Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acid Sphingomyelinase Inhibition to Mitigate the Environmental Exposure Risks of Ultraviolet Light-Induced Actinic Neoplasia and Squamous Cell Carcinoma in US Veterans

NCT06778434 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

NCT NCT06778434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06778434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acid Sphingomyelinase Inhibition to Mitigate the Environmental Exposure Risks of Ultraviolet Light-Induced Actinic Neoplasia and Squamous Cell Carcinoma in US Veterans
Lead sponsor
VA Office of Research and Development
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2025
Completion date
March 30, 2029
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis, imipramine, photodynamic therapy